SMYD3 Antibody

What types of SMYD3 antibodies are available for research applications?

Researchers have several options when selecting SMYD3 antibodies:

• Polyclonal antibodies: Available as rabbit anti-human SMYD3 antibodies that recognize the full protein or specific domains. These typically offer good sensitivity across multiple applications .

• Monoclonal antibodies: Mouse monoclonal IgG2b antibodies (like the C-3 clone) that detect SMYD3 protein from multiple species including human, mouse, and rat .

• Application-specific formats: SMYD3 antibodies are available in various conjugated forms, including agarose, HRP, PE, FITC, and multiple Alexa Fluor® conjugates for specialized applications .

When selecting an antibody, consider its validated applications (WB, IP, ChIP, ICC/IF) and the specific experimental requirements.

How should I validate the specificity of a SMYD3 antibody?

Proper validation is critical for ensuring reliable results:

• Western blot analysis: Verify a single band at the expected molecular weight (49 kDa) in relevant cell lines. Compare results with positive control cell lines known to express SMYD3 (A549, SK-OV-3, HCT 116) .

• Knockdown/knockout controls: Use SMYD3 siRNA or CRISPR-mediated knockout cells as negative controls .

• Immunoprecipitation validation: Confirm specificity through IP followed by Western blot. Compare with non-specific IgG controls .

• Cross-reactivity testing: Test the antibody against related SMYD family proteins to ensure specificity.

Which experimental applications are SMYD3 antibodies suitable for?

Based on validated applications across multiple sources:

How can I use SMYD3 antibodies to investigate its oncogenic role in cancer?

SMYD3 is overexpressed in multiple cancer types, including colorectal, lung, and head and neck squamous cell carcinoma:

• Expression analysis: Use Western blot to compare SMYD3 expression between normal cells (e.g., NCM460 normal colonocytes) and cancer cell lines (e.g., HT29, HCT116) .

• Functional studies: Combine SMYD3 antibody detection with knockdown/inhibition approaches to assess effects on:

  • Cell proliferation and clonal capacity

  • Cell cycle progression

  • Invasive potential

• Target gene regulation: Use ChIP assays with SMYD3 antibodies to identify direct gene targets that promote oncogenesis .

• Pathway analysis: Investigate SMYD3's role in specific oncogenic pathways like MAPK signaling and epithelial-mesenchymal transition (EMT) .

What methodological approaches are recommended for ChIP experiments with SMYD3 antibodies?

Chromatin immunoprecipitation (ChIP) is crucial for studying SMYD3's direct interaction with target genes:

• Optimization strategies:

  • Cross-linking: Standard 1% formaldehyde for 10 minutes at room temperature

  • Sonication: Optimize to achieve 200-500 bp DNA fragments

  • Antibody amount: 5 μg of SMYD3 antibody per ChIP reaction has been successful

• Advanced techniques:

  • CUT&RUN (Cleavage Under Targets and Release Using Nuclease) assays provide higher resolution mapping of SMYD3 binding sites

  • Sequential ChIP can identify co-occupancy with other factors such as SMAD3

  • Analyze histone modifications (H3K4me3, H3K9ac) at SMYD3-bound regions to correlate with gene activation

• Target gene analysis:

  • Key EMT-related genes: Snail1 promoter is a well-validated target for SMYD3 binding

  • Cell cycle regulators: Analyze SMYD3 occupancy at cell cycle-promoting genes

How can I investigate SMYD3 protein interactions using immunoprecipitation approaches?

SMYD3 functions through interactions with other proteins:

• Co-immunoprecipitation protocol:

  • Lyse cells in non-denaturing buffer (preserves protein-protein interactions)

  • Use 5 μg of SMYD3 antibody per IP reaction

  • Include appropriate controls (non-specific IgG)

  • Analyze by Western blot for interacting partners

• Validated interactions:

  • SMAD3: Direct interaction involves the MH2 domain of SMAD3 and the C-terminal region of SMYD3

  • RNA polymerase complex components

  • HSP90A: Enhances SMYD3 methyltransferase activity

• Domain mapping:

  • Use deletion mutants to map interaction domains (e.g., SMYD3_219-428 and SMYD3_111-428 associate with SMAD3, while SMYD3_1-219 and SMYD3_1-380 do not)

  • C-terminal region (aa 380-428) of SMYD3 is critical for SMAD3 interaction

How can I evaluate SMYD3's role in cancer progression and metastasis?

SMYD3 promotes epithelial-mesenchymal transition and invasiveness:

• EMT marker analysis:

  • Use Western blot with SMYD3 antibody alongside EMT markers (E-cadherin, N-cadherin, Fibronectin, Claudin6)

  • Assess changes in marker expression upon SMYD3 inhibition or knockdown

• Migration and invasion assays:

  • Transwell migration assays show reduced migration in BCI121-treated or SMYD3-depleted cells

  • In vivo zebrafish xenograft models demonstrate SMYD3's role in invasive ability

• Clinical correlation:

  • Higher SMYD3 levels correlate with less favorable prognosis in claudin-low breast cancers

  • SMYD3 expression is associated with reduced metastasis-free survival in breast cancer patients

What methods can I use to study SMYD3 inhibition as a therapeutic approach?

Small molecule inhibitors of SMYD3 show promise as potential cancer therapeutics:

• Inhibitor studies:

  • BCI-121 is a validated SMYD3 inhibitor that reduces SMYD3 activity both in vitro and in cells

  • Assess H3K4me2/3 and H4K5me levels by Western blot as markers of SMYD3 inhibition

• Functional readouts:

  • Cell viability: Trypan blue exclusion assay shows dose-dependent effects of SMYD3 inhibitors

  • Colony formation: Crystal violet staining quantifies survival fraction after inhibitor treatment

  • EMT gene expression: qRT-PCR analysis of mesenchymal markers following inhibitor treatment

• Combined approaches:

  • Compare pharmacological inhibition with genetic ablation (siRNA/shRNA) to confirm target specificity

  • Test inhibitors across multiple cancer cell lines to establish broad applicability

How do I optimize immunofluorescence detection of SMYD3 protein?

For successful subcellular localization studies:

• Fixation methods:

  • Ice-cold methanol fixation has been validated for SMYD3 detection in HCT116 cells

  • Compare with 4% paraformaldehyde fixation to determine optimal preservation

• Antibody dilution and incubation:

  • Start with 1/500 dilution for most SMYD3 antibodies

  • Incubate overnight at 4°C for optimal signal-to-noise ratio

• Detection and imaging:

  • SMYD3 shows predominantly cytoplasmic localization in some cancer cell lines

  • Use nuclear counterstain (e.g., Hoechst 33342) to assess nuclear vs. cytoplasmic distribution

What are the critical factors for successful Western blot detection of SMYD3?

To obtain clean, specific signals:

• Lysate preparation:

  • Total cell lysates from cancer cell lines (A549, SK-OV-3, HCT116) provide good positive controls

  • Use 30 μg total protein per lane for optimal detection

• Gel selection and transfer:

  • 10% SDS-PAGE has been validated for SMYD3 detection

  • SMYD3 has a predicted band size of 49 kDa

• Antibody dilution:

  • Primary antibody: 1/1000 dilution is typically effective for Western blot

  • Secondary antibody: HRP-conjugated anti-rabbit or anti-mouse IgG depending on primary

• Signal detection:

  • Enhanced chemiluminescence (ECL) provides sufficient sensitivity for most applications

  • For quantitative analysis, consider fluorescent secondary antibodies and imaging systems

How can I resolve contradictory results when studying SMYD3 function?

When facing inconsistent findings:

• Antibody validation:

  • Different antibodies may recognize different epitopes or isoforms

  • Validate multiple antibodies against the same samples

  • Consider monoclonal antibodies for highest specificity

• Cell type differences:

  • SMYD3 expression varies significantly across cell types

  • Compare results in multiple cell lines (e.g., LS174T and DLD-1 show low SMYD3 levels while HT29, HCT116, SW480, Caco-2, and LoVo show high expression)

• Context-dependent functions:

  • SMYD3 may have different roles in different cellular contexts

  • In innate immunity, Smyd3 negatively regulates antiviral pathways by promoting TAK1 degradation

  • In cancer, SMYD3 promotes cell proliferation and EMT

How can I investigate SMYD3's role in innate immune responses?

Recent findings suggest SMYD3 functions beyond cancer:

• Knockdown/overexpression studies:

  • siRNA-mediated Smyd3 silencing promotes expression of IL-8, IL-1β, ISG15, MX1, and viperin in response to immune stimuli

  • Overexpression of Smyd3 suppresses these immune response genes

• Interaction with innate immune signaling components:

  • SMYD3 specifically degrades TAK1 without affecting other adapters in the pathway

  • Co-immunoprecipitation reveals SMYD3 directly interacts with TAK1 via its STK domain

• Domain mapping:

  • Use deletion mutants to identify functional domains:

    • The STK domain of TAK1 is required for SMYD3 binding and regulation

    • SMYD3 cannot bind to or regulate TAK1 without this domain

What methodologies can I use to identify novel SMYD3 methylation targets?

Beyond histones, SMYD3 may methylate non-histone proteins:

• Protein methylation assays:

  • In vitro methyltransferase assays with recombinant SMYD3 and candidate substrates

  • Mass spectrometry to identify methylation sites on target proteins

• Target identification approaches:

  • Immunoprecipitation of SMYD3 followed by mass spectrometry to identify interacting partners

  • Protein arrays incubated with active SMYD3 to identify potential methylation targets

• Functional validation:

  • Site-directed mutagenesis of candidate methylation sites

  • Functional assays to determine the consequence of methylation on target protein activity

  • Analysis of methylation-defective SMYD3 mutants (e.g., SMYD3_ΔEEL)

How should I approach studying SMYD3 in the context of precision medicine?

SMYD3 inhibitors show promise as targeted cancer therapeutics:

• Patient-derived models:

  • Analyze SMYD3 expression in patient tumor samples

  • Test SMYD3 inhibitors in patient-derived xenografts or organoids

• Biomarker identification:

  • Determine whether SMYD3 expression correlates with response to specific therapies

  • Identify gene signatures associated with SMYD3 activity that predict treatment response

• Combination approaches:

  • Test SMYD3 inhibitors in combination with other therapies

  • SMYD3 inhibition may enhance response to immunotherapy in HPV-negative HNSCC

  • Investigate synergistic effects with standard chemotherapeutics